Meghan D Morris1, Ali Mirzazadeh2, Jennifer L Evans3, Alya Briceno3, Phillip Coffin4, Judith A Hahn5, Kimberly A Page6. 1. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Meghan.Morris@ucsf.edu. 2. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA. 3. Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA. 4. San Francisco Department of Public Health, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. 6. Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Abstract
OBJECTIVE: To understand the number of young adult people who inject drugs (PWID) with hepatitis C virus (HCV) infection accessing direct-acting antiviral (DAA) treatment and their barriers and facilitators to treatment uptake. METHODS: Using prospective cohort data from young adult PWID in San Francisco with newly identified HCV infection, we calculated the number who: (i) accepted referral to DAA therapy, (ii) initiated DAA therapy, (iii) completed DAA therapy, and (iv) achieved sustained virologic response (SVR) or cure. Behavioral survey data identified possible barriers and facilitators to DAA therapy. RESULTS: Of 60 young adult PWID with new HCV infection identified between February 2015 and January 2018, thirty accepted a referral to HCV care; five initiated and completed HCV treatment and achieved cure. Barriers to DAA uptake included fear of medical establishments, competing basic needs, and delaying care because they were feeling well. CONCLUSION: While few HCV-positive young adult PWID engaged in DAA therapy, all those who did achieved cure. Youth-tailored services that overcome the stigma and marginalization related to injection drug use are needed to improve treatment uptake.
OBJECTIVE: To understand the number of young adult people who inject drugs (PWID) with hepatitis C virus (HCV) infection accessing direct-acting antiviral (DAA) treatment and their barriers and facilitators to treatment uptake. METHODS: Using prospective cohort data from young adult PWID in San Francisco with newly identified HCV infection, we calculated the number who: (i) accepted referral to DAA therapy, (ii) initiated DAA therapy, (iii) completed DAA therapy, and (iv) achieved sustained virologic response (SVR) or cure. Behavioral survey data identified possible barriers and facilitators to DAA therapy. RESULTS: Of 60 young adult PWID with new HCV infection identified between February 2015 and January 2018, thirty accepted a referral to HCV care; five initiated and completed HCV treatment and achieved cure. Barriers to DAA uptake included fear of medical establishments, competing basic needs, and delaying care because they were feeling well. CONCLUSION: While few HCV-positive young adult PWID engaged in DAA therapy, all those who did achieved cure. Youth-tailored services that overcome the stigma and marginalization related to injection drug use are needed to improve treatment uptake.
Authors: Stefan Christensen; Peter Buggisch; Stefan Mauss; Klaus H W Böker; Eckart Schott; Hartwig Klinker; Tim Zimmermann; Bernd Weber; Jens Reimer; Yvonne Serfert; Heiner Wedemeyer Journal: Addiction Date: 2018-01-23 Impact factor: 6.526
Authors: Holly Hagan; Enrique R Pouget; Ian T Williams; Richard L Garfein; Steffanie A Strathdee; Sharon M Hudson; Mary H Latka; Lawrence J Ouellet Journal: J Infect Dis Date: 2010-02-01 Impact factor: 5.226
Authors: Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: Jason Grebely; Julie Bruneau; Philip Bruggmann; Magdalena Harris; Matthew Hickman; Tim Rhodes; Carla Treloar Journal: Int J Drug Policy Date: 2017-09
Authors: Shelley N Facente; Eduard Grebe; Katie Burk; Meghan D Morris; Edward L Murphy; Ali Mirzazadeh; Aaron A Smith; Melissa A Sanchez; Jennifer L Evans; Amy Nishimura; Henry F Raymond Journal: PLoS One Date: 2018-04-11 Impact factor: 3.240
Authors: Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman Journal: Hepatology Date: 2013-08-26 Impact factor: 17.425
Authors: Claire E Kendall; Michael Fitzgerald; Jessy Donelle; Jeffrey C Kwong; Chrissi Galanakis; Rob Boyd; Curtis L Cooper Journal: Can Liver J Date: 2020-06-04
Authors: Daniel Winetsky; Daniel Burack; Pantelis Antoniou; Bill Garcia; Peter Gordon; Matthew Scherer Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Phillip O Coffin; Glenn-Milo Santos; Emily Behar; Jaclyn Hern; John Walker; Tim Matheson; Elizabeth N Kinnard; Janelle Silvis; Eric Vittinghoff; Rena Fox; Kimberley Page Journal: PLoS One Date: 2019-06-03 Impact factor: 3.240
Authors: Alison R Ohringer; David P Serota; Rachel L McLean; Lauren J Stockman; James P Watt Journal: BMC Public Health Date: 2021-07-21 Impact factor: 3.295
Authors: Jennifer R Havens; Takako Schaninger; Hannah Fraser; Michelle Lofwall; Michele Staton; April M Young; Ardis Hoven; Sharon L Walsh; Peter Vickerman Journal: BMJ Open Date: 2021-07-05 Impact factor: 2.692